Advanced in Lymphoid Hyperplasia

Dr. Anita J. Kumar

Hematology Oncology | Hematology | Oncology
Memorial Hematology Lymphoma Group
530 E 74th St, 
New York, NY 
Accepting New Patients
Offers Telehealth
17 Years of Experience
Advanced in Lymphoid Hyperplasia
Memorial Hematology Lymphoma Group
530 E 74th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anita Kumar is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Kumar has been practicing medicine for over 17 years and is rated as an Advanced provider by MediFind in the treatment of Lymphoid Hyperplasia. Her top areas of expertise are Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kumar is currently accepting new patients.

Her clinical research consists of co-authoring 121 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Year
2008
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

MEMORIAL HEMATOLOGY LYMPHOMA GROUP
530 E 74th St, New York, NY 10021
Other Locations
MEMORIAL SLOAN KETTERING CANCER CENTER AT BASKING RIDGE NEW JERSEY
136 Mountainview Blvd, Basking Ridge, NJ 07920
MEMORIAL HEMATOLOGY LYMPHOMA GROUP
1275 York Ave, New York, NY 10065

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Procedure, Radiation, Drug
Study Drugs: Brentuximab, Doxorubicin, Vinblastine, Dacarbazine
Study Phase: Not Applicable
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2025
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Enrollment Status: Active_not_recruiting
Publish Date: November 04, 2024
Intervention Type: Other, Device
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study
Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma: A Phase II Study
Enrollment Status: Completed
Publish Date: August 30, 2024
Intervention Type: Drug
Study Drugs: Lenalidomide, Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, High-Dose Cytarabine (HIDAC)
Study Phase: Phase 2
A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
A Phase I and Randomized Phase II Study of KW-0761 (Mogamulizumab) and MK-3475 (Pembrolizumab) in Relapsed, Refractory Diffuse Large-B Cell Lymphoma
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological
Study Drugs: Mogamulizumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 09, 2023
Intervention Type: Drug
Study Drug: Ibrutinib
Study Phase: Phase 1
View 5 Less Clinical Trials

121 Total Publications

Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.
Outcomes of T-cell/histiocyte-rich large B-cell lymphoma treated with higher-intensity therapy in the rituximab era: insights from a retrospective analysis.
Journal: Leukemia & lymphoma
Published: July 02, 2025
Similar Doctors
Distinguished in Lymphoid Hyperplasia
Dr. Philip C. Caron
Oncology | Hematology
Distinguished in Lymphoid Hyperplasia
Dr. Philip C. Caron
Oncology | Hematology

Msk Harrison

500 Westchester Ave, 
West Harrison, NY 
 (21.3 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Philip Caron is an Oncologist and a Hematologist in West Harrison, New York. Dr. Caron is rated as a Distinguished provider by MediFind in the treatment of Lymphoid Hyperplasia. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Follicular Lymphoma, and Diffuse Large B-Cell Lymphoma (DLBCL).

Distinguished in Lymphoid Hyperplasia
Dr. Matthew J. Matasar
Oncology | Hematology Oncology | Hematology
Distinguished in Lymphoid Hyperplasia
Dr. Matthew J. Matasar
Oncology | Hematology Oncology | Hematology

Rutgers Health-Rwj Scleroderma Program

195 Little Albany St, 
New Brunswick, NJ 
 (32.1 miles away)
732-235-2465
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Matasar is an Oncologist and a Hematologist Oncology provider in New Brunswick, New Jersey. Dr. Matasar is rated as an Elite provider by MediFind in the treatment of Lymphoid Hyperplasia. His top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma, B-Cell Lymphoma, and Bone Marrow Transplant. Dr. Matasar is currently accepting new patients.

Advanced in Lymphoid Hyperplasia
Dr. Colette N. Owens
Hematology | Oncology
Advanced in Lymphoid Hyperplasia
Dr. Colette N. Owens
Hematology | Oncology

Msk Monmouth

480 Red Hill Rd, 
Middletown, NJ 
 (29.3 miles away)
908-542-3007
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Colette Owens is a Hematologist and an Oncologist in Middletown, New Jersey. Dr. Owens is rated as a Distinguished provider by MediFind in the treatment of Lymphoid Hyperplasia. Her top areas of expertise are Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), B-Cell Lymphoma, and Follicular Lymphoma. Dr. Owens is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 9 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile